SVRA

Savara Inc

SVRA, USA

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

https://www.savarapharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SVRA
stock
SVRA

Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy simplywall.st

Read more →
SVRA
stock
SVRA

Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10.3125

Analyst Picks

Strong Buy

4

Buy

2

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

15.87

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-31.32 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-20.98 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

High

0.49

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 93.48% of the total shares of Savara Inc

1.

NEA Management Company, LLC

(14.1586%)

since

2025/06/30

2.

Bain Capital Life Sciences Investors, LLC

(10.1834%)

since

2025/06/30

3.

TCG Crossover Management, LLC

(7.1525%)

since

2025/06/30

4.

Vestal Point Capital LP

(6.3731%)

since

2025/06/30

5.

BlackRock Inc

(5.656%)

since

2025/06/30

6.

VR Adviser, LLC

(5.1403%)

since

2025/06/30

7.

Vanguard Group Inc

(4.8913%)

since

2025/06/30

8.

Nantahala Capital Management, LLC

(4.8169%)

since

2025/06/30

9.

Deerfield Management Co

(4.6078%)

since

2025/06/30

10.

Farallon Capital Management, L.L.C.

(3.9546%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(2.952%)

since

2025/07/31

12.

ADAR1 Capital Management LLC

(2.0833%)

since

2025/06/30

13.

Emerald Advisers, LLC

(2.0449%)

since

2025/06/30

14.

Wellington Management Company LLP

(1.9384%)

since

2025/06/30

15.

iShares Russell 2000 ETF

(1.7544%)

since

2025/08/31

16.

Geode Capital Management, LLC

(1.7185%)

since

2025/06/30

17.

Rosalind Advisors, Inc.

(1.5361%)

since

2025/06/30

18.

Sofinnova Ventures

(1.4218%)

since

2025/06/30

19.

State Street Corp

(1.4215%)

since

2025/06/30

20.

Emerald Mutual Fund Advisers Trust

(1.265%)

since

2025/06/30

21.

Sphera Funds Management Ltd.

(0.7581%)

since

2025/06/30

22.

Fidelity Small Cap Index

(0.7343%)

since

2025/06/30

23.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7279%)

since

2025/07/31

24.

iShares Russell 2000 Growth ETF

(0.661%)

since

2025/08/31

25.

SUPERSTRING CAPITAL MANAGEMENT LP

(0.6453%)

since

2025/06/30

26.

UTM IM GBP AXA Framlington Biotech

(0.5829%)

since

2025/07/31

27.

Emerald Growth A

(0.5807%)

since

2025/07/31

28.

Principal SmallCap Growth I Instl

(0.5355%)

since

2025/07/31

29.

Fidelity Extended Market Index

(0.3648%)

since

2025/07/31

30.

DWS ESG Biotech LC

(0.3587%)

since

2025/07/31

31.

Vanguard Russell 2000 ETF

(0.349%)

since

2025/07/31

32.

MEDICAL BioHealth EUR Acc

(0.3329%)

since

2025/06/30

33.

Schwab US Small-Cap ETFâ„¢

(0.3155%)

since

2025/08/30

34.

iShares Biotechnology ETF

(0.2672%)

since

2025/08/31

35.

Small Cap Growth / Emerald Fund SP

(0.2266%)

since

2025/06/30

36.

Wellington CIF II SMID Cap Research

(0.2014%)

since

2025/03/31

37.

Voya Small Company Port I

(0.1948%)

since

2025/07/31

38.

State St Russell Sm Cap® Indx SL Cl I

(0.1943%)

since

2025/08/31

39.

Schwab Small Cap Index

(0.1905%)

since

2025/07/31

40.

F/m Emerald Life Sciences Innovation ETF

(0.1885%)

since

2025/08/29

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.14

EPS Estimate

-0.13

EPS Difference

-0.01

Surprise Percent

-7.6923%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.